FLURBIPROFEN

Search structure
Trade Names:
Synonyms:
Status: Approved (1986)
Entry Type: Small molecule
Molecule Category: Parent
ATC: M01AE09
UNII: 5GRO578KLP

Structure
InChI Key SYTBZMRGLBWNTM-UHFFFAOYSA-N
Smile CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
InChI
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)

Physicochemical Descriptors

Property Name Value
Molecular Formula C15H13FO2
Molecular Weight 244.26
AlogP 3.68
Hydrogen Bond Acceptor 1.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 3.0
Polar Surface Area 37.3
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 18.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Cyclooxygenase inhibitor PubMed PubMed PubMed PubMed PubMed PubMed
Primary Target
COX-1
COX-2
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Auxiliary transport protein Fatty acid binding protein family
- - - 1180 -
Enzyme Hydrolase
- - - - 16
Enzyme Oxidoreductase
- 10-1995 - 1000 -
Enzyme
- 10-1995 - 1000 16
Membrane receptor
- - - - 7-30
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 227

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Pain 3 D010146 ClinicalTrials
Pharyngitis 3 D010612 ClinicalTrials
Low Back Pain 2 D017116 ClinicalTrials
Periodontitis 2 D010518 ClinicalTrials
Mitochondrial Diseases 1 D028361 ClinicalTrials
Anemia 1 D000740 ClinicalTrials
Arthritis, Rheumatoid 1 D001172 ClinicalTrials
HIV Infections 1 D015658 ClinicalTrials
Diabetes Mellitus, Type 2 1 D003924 ClinicalTrials

Related Entries

MCS

Scaffolds

Salt

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
18.15
Immune system disorders
15.94
Respiratory, thoracic and mediastinal disorders
13.25
Skin and subcutaneous tissue disorders
12.35
General disorders and administration site conditions
5.89
Vascular disorders
4.74
Cardiac disorders
4.42
Injury, poisoning and procedural complications
3.6
Nervous system disorders
3.6
Investigations
2.78
Eye disorders
2.62
Psychiatric disorders
2.29
Renal and urinary disorders
2.29

Cross References

Resources Reference
CAS NUMBER 5104-49-4
ChEBI 5130
ChEMBL CHEMBL563
DrugBank DB00712
DrugCentral 1219
EPA CompTox DTXSID0037231
FDA SRS 5GRO578KLP
Human Metabolome Database HMDB0014850
Guide to Pharmacology 4194
KEGG D00330
PDB FLP
PharmGKB PA449683
PubChem 3394
SureChEMBL SCHEMBL2248
ZINC ZINC00008667
CONTENTS